CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 155 enrolled
Drug / intervention
CT001drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06364072
NCT06364072Phase 3Completed
CompareCT.gov

Open-label, Prospective Study to Assess the Safety, Tolerability, Analgesic Effect and Feasibility of Intranasal Sufentanil/Ketamine in Pediatric Patients With Moderate or Severe Pain, in an Acute Care Setting

Cessatech A/S·interventional·Posted Apr 15, 2024·Updated Feb 2, 2026

In Brief

A Phase 3 clinical trial evaluating CT001 for Pain. Completed, enrolled 155 participants across 7 sites in 2 countries.

Detailed Summary

The proposed study aims to investigate the safety, tolerability, analgesic efficacy, and feasibility of intranasal sufentanil/ketamine (CT001) in pediatric participants attending an acute care (i.e. emergency) setting. The study is a part of the clinical development plan for the development of CT001 nasal spray for treatment of acute pain in children.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPain
CountriesSpain, United Kingdom
Collaborators--

Timeline

Phase 3CompletedFinished
20252026
First PostedApr 15, 2024
Enrollment StartMay 27, 2024
Primary CompletionMay 9, 2025
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 2.2 years ago

Interventions

CT001drug

Intranasal